NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this publication.

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 18, No. 23
July 7, 1989
NOTICES

CONFERENCE ANNOUNCEMENT: DIABETES IN AMERICAN INDIANS AND ALASKA NATIVES .............................................................. 1
Indian Health Service
National Institute of Diabetes and Digestive and Kidney Diseases
Index: INDIAN HEALTH SERVICE
DIABETES, DIGESTIVE AND KIDNEY DISEASES

NEW PROPHET WORKSTATION SOFTWARE AVAILABLE ..................... 1
Division of Research Resources
Index: RESEARCH RESOURCES

DATED ANNOUNCEMENTS (RFPs AND RFAs)

EVALUATION OF COMMONLY USED ORTHOGNATIC TREATMENT PROCEDURES (RFA) ........... 2
National Institute of Dental Research
Index: DENTAL RESEARCH

ANIMAL FACILITY IMPROVEMENTS FOR SMALL RESEARCH PROGRAMS (RFA) .............. 3
Division of Research Resources
Index: RESEARCH RESOURCES

ONGOING PROGRAM ANNOUNCEMENTS

DEVELOPMENT OF MEDICATION--MEDICINAL CHEMISTRY CONSIDERATIONS ............ 4
National Institute on Drug Abuse
Index: DRUG ABUSE
CONFERENCE ANNOUNCEMENT: DIABETES IN AMERICAN INDIANS AND ALASKA NATIVES

P.T. 42, FA, FE; K.W. 0715075

Indian Health Service
National Institute of Diabetes and Digestive and Kidney Diseases

November 14-17, 1989, Mesa, Arizona

Conference Goals:

- to assess progress, needs, and opportunities in diabetes research and health care delivery in American Indians and Alaska Natives;
- to encourage collaboration between scientists, health care professionals, and tribal/community leaders in developing new research proposals related to the diagnosis, treatment, and prevention of diabetes and its complications in these populations;
- to facilitate the transfer of current research knowledge to medical practice, and to inform tribal and community leaders of opportunities for the reduction of diabetes-related morbidity and mortality.

Conference Topics:

- Biological Diversity Among American Indians and Alaska Natives
- Diabetes in American Indians: Tribal and Regional Differences
- Complications of Diabetes Among American Indians
- Risk Factors and Pathogenesis of non-insulin dependent diabetes mellitus (NIDDM) Among American Indians
- Research Opportunities: Prevention and Early Treatment Treatment of Complications

We particularly encourage attendance by investigators who are interested in applying their knowledge and skills to emerging research opportunities associated with diabetes in Native Americans, either as independent investigators or potentially as participants in a cooperative, multicenter research program. Limited travel funds are available to assist both new and established investigators who might be expected to make important contributions to this area of research in the future and who have no other available source of support. Applications for travel funds should be submitted in the form of a curriculum vitae appended to a letter that summarizes the applicant's interest in this conference and the potential commitment/contribution that he/she might make to this area of research. Applications must be received by the Conference Coordinator no later than September 1, 1989. All conference participants should preregister by October 1, 1989, to ensure hotel accommodations.

The conference program, registration materials, and additional information regarding the conference are available from:

Raymond Kuehne, Conference Coordinator
Diabetes in American Indians and Alaska Natives
1801 Rockville Pike, Suite 500
Rockville, Maryland 20852
Telephone: (301) 496-6045

NEW PROPHET WORKSTATION SOFTWARE AVAILABLE

P.T. 34, 36; K.W. 0780018, 1003001, 0790010, 1002008, 1002034, 0710100, 0706000

Division of Research Resources

The Biomedical Research Technology Program is now making its low-cost PROPHET data management, analysis and visualization package widely available. Increased research productivity is the goal through the appropriate and wide-spread use of powerful networked workstations and PROPHET's comprehensive capabilities.

The package is fully documented, engineered and supported by scientific software professionals. It offers features for many biomedical scientists including:
Tabular data management and spread-sheet-like calculation
- Color graphics and scientific visualization
- Statistical and mathematical modeling
- Molecular structure databases, modeling and display
- Nucleic and amino acid sequence manipulation and databases
- Advanced user interface and user customization
- Network access for email, sharing data, and NSFnet supercomputers
- Organized user group and electronic bboard

PROPHET has been used in many disciplines including:
- Biochemistry
- Clinical research
- Molecular biology
- Physiology
- Pharmacology
- Biomedical engineering

The software is available for a variety of Unix workstations currently Sun 3s and 4s and DEC Ulitrix hosts, VaxStations and the DECStation 3100 and also supports the X11 and SunView window systems. Further ports and continuing enhancements are planned including interfaces to standard SQL databases, and SAS. For further information please contact:

Dr. Richard DuBois
Biomedical Research Technology Program
Division of Research Resources
Westwood Building, Room 8A-15
National Institutes of Health
5333 Westbard Ave.
Bethesda, Maryland 20892
Telephone: (301) 496-5411

DATED ANNOUNCEMENTS (RFPs AND RFAs)

EVALUATION OF COMMONLY USED ORTHOGNATHIC TREATMENT PROCEDURES

RFA AVAILABLE: 89-DE-1
P.T. 34; K.W. 0755015, 0785040, 0710120, 0414000, 1010013
National Institute of Dental Research
Application Receipt Date: January 15, 1990
The Craniofacial Anomalies, Pain Control And Behavioral Research Branch of the National Institute of Dental Research (NIDR) seeks research grant (R01) applications to conduct clinical trials evaluating commonly used orthognathic treatment procedures.

In order to obtain sufficiently large samples, it is likely that such trials would involve consortium arrangements, directed from major treatment centers. Investigative teams might include specialists in oral, maxillofacial and plastic surgery, orthodontics, prosthodontics, psychology, speech pathology, clinical epidemiology and biostatistics.

This RFA is for a single competition with a receipt date of January 15, 1990. It is anticipated that up to three awards will be made, if a sufficient number of high quality applications is received. The earliest funding date is July 1, 1990.

Applications should be prepared and submitted in accordance with the objectives and requirements described in the full RFA, available from:

John D. Townsley, Ph.D.
Extramural Program
Westwood Building, Room 506
National Institute of Dental Research
National Institutes of Health
Bethesda, Maryland 20892-4500
Telephone: (301) 496-7807
ANIMAL FACILITY IMPROVEMENTS FOR SMALL RESEARCH PROGRAMS

RFA AVAILABLE: 89-RR-03
P.T. 34; K.W. 1002002, 0201011

Division of Research Resources
Application Receipt Date: December 4, 1989

BACKGROUND

The Division of Research Resources (DRR) is announcing a competitive grant program to help institutions with small research programs using animals to upgrade and develop their animal facilities.

RESEARCH GOALS AND SCOPE

Institutional animal resource improvement grants are awarded to assist biomedical research and educational institutions in upgrading their animal facilities and developing a centralized animal care program. A major objective is to enable institutions to comply with the USDA Animal Welfare Act and DHHS policies on the care and treatment of animals. These awards are limited to Alterations and Renovations (A&R) to improve laboratory animal facilities, and related major resource equipment, such as animal cages and cage washers.

To gain approval and support, the need for resource improvement, as well as a sound plan to meet the requirements of the Public Health Service Policy on Humane Care and Use of Laboratory Animals, must be presented and described in the context of the biomedical research and research training program of the institution.

ELIGIBILITY AND REVIEW

Any domestic public, or private institution, organization or association, with one or more research projects that involves the use of laboratory animals and is supported by the Public Health Service (PHS) at the time of award, is eligible to apply. The total PHS support in the last fiscal year for projects using animals must have been less than $500,000. Institutions are expected to develop a single proposal for campus-wide service.

Applications will be received by the Division of Research Grants. Applicants must use Form PHS 398 (rev. 10/88), "Application for Public Health Service Grant." There will be a single receipt date of December 4, 1989. Applications received after this date will be returned. The RFA label available in the Application Form PHS 398 must be affixed to the bottom of the face page. All applications submitted in response to this Request for Applications (RFA) will be reviewed by Special Review Committees managed by DRR for scientific merit, and the National Advisory Research Resources Council for program considerations. Earliest possible funding will be July, 1990.

MECHANISM OF SUPPORT

Awards will be made as competitive resource grants for a project period of one year. It is expected that six to eight awards will be made in Fiscal Year 1990. The number of grants and the specific amount of the awards will depend on the merit and scope of the applications received, as well as the availability of funds. All policies and requirements which govern the grant programs of the PHS apply.

TERMS OF AWARD

Institutions may request major equipment items for their animal resources as well as funds for A&R. Support for new construction is not authorized. The award is limited to $100,000 for A&R and $150,000 for equipment. Matching funds are not required. Funds awarded for A&R may not be obligated until final architectural drawings, specifications, and updated cost estimates are received and approved by the Division of Research Resources.

INQUIRIES

A copy of the complete RFA, which describes the research goals and scope, terms and conditions, review procedures and criteria, and method of applying, may be obtained by contacting the Animal Resources Program, DRR.

Vol. 18, No. 23, July 7, 1989 - Page 3
Director
Laboratory Animal Sciences Program
Animal Resources Program Branch
Division of Research Resources
5333 Westbard Avenue, Room 853
Bethesda, Maryland 20892

This program is described in the Catalog of Federal Domestic Assistance No. 13.306, Laboratory Animal Sciences Primate Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review of Executive Order 12372 or Health Systems Agency review.

ONGOING PROGRAM ANNOUNCEMENTS

DEVELOPMENT OF MEDICATION—MEDICINAL CHEMISTRY CONSIDERATIONS

P.T. 34; K.W. 0710080, 0404009, 0755025

National Institute on Drug Abuse

Purpose

There is a need for new medications for the treatment of drug abuse and related disorders. New medications are needed which substitute for abused drugs in clinical treatment programs, block the psychotropic effects of abused drugs, reduce the craving for abused drugs, moderate and/or eliminate the process of withdrawal from abused drugs, and block and/or reverse the toxic effects of abused drugs.

New grant applications are solicited from the design and synthesis of new drug moieties for all classes of drugs of abuse including cocaine and related compounds, opioids, PFC and related compounds, cannabinoids, and benzodiazepines.

Research Objectives

This program will support studies which involve rational design of new therapeutic entities by application of structure-activity relationship (SAR) studies, synthesis of analogs, screening for bioactivity, and preliminary studies to determine metabolism and bioavailability followed by dosage development/utilization of new techniques such as computer-aided drug design (CADD) are strongly encouraged for these efforts. In addition, there is a need for the design of affinity labels to reveal receptor populations using positron emission tomography (PET) and other imaging procedures as diagnostic tools in normal and addicted populations, the development of new computer-assisted techniques for receptor mapping and utilization of theoretical methods to design new drugs and molecular probes.

Priority areas include the synthesis of drugs to treat the toxic side effects of drugs of abuse (such as drugs to treat cardiotoxicity of cocaine), synthesis of Mu-1 receptor specific opioids, synthesis of cannabinoid and cocaine antagonists, synthesis of sigma/PCP receptor specific analogs, and synthesis of PCP receptor ligands that antagonize N-methyl-D-aspartate receptors (NMDA).

Research Support Mechanisms

Support mechanisms include: (1) research projects (R01), (2) program projects (P01), (3) small grants (R03), and (4) first independent research support and transition awards (R29). For details on a particular support mechanism or program, please contact the member of the program or review staff listed at the end of the announcement.

Eligibility

Application for research grants may be made by any public or private non-profit or for-profit institution such as universities, colleges, hospitals, laboratories, units of state or local government, private industry and eligible agencies of the Federal government.

The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) urges applicants for grants to give added attention (where feasible and appropriate), to the inclusion of women and minority populations.
Investigators should include sufficient women and minority group participants to permit generalization of results to the referenced populations. If women and minorities are not included in a given study, a clear rationale for their exclusion must be provided.

Application Process

Applicants interested in submitting P01 applications are strongly urged to consult the program staff listed at the end of this announcement, prior to preparing an application. Additional information for the preparation of the application and review criteria may be obtained from the review staff listed at the end of this announcement. State and local government agencies may use Form PHS 5161-1 (Rev. 11/88). All other applicants should use the grant application Form 398 (Rev. 10/88). The title of this program announcement, Development of Medications-- Medicinal Chemistry Considerations, should be typed in item number 2 on the face page of the PHS 398 application form or in item 9 in PHS 5161-1 term.

Receipt and Review Schedule

<table>
<thead>
<tr>
<th>Receipt Dates</th>
<th>Initial Review</th>
<th>Advisory Council Review</th>
<th>Earliest Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 1/July 1*</td>
<td>Oct/Nov</td>
<td>Jan/Feb</td>
<td>Apr 1</td>
</tr>
<tr>
<td>Oct. 1/Nov. 1*</td>
<td>Feb/Mar</td>
<td>May/June</td>
<td>July 1</td>
</tr>
<tr>
<td>Feb. 1/Mar. 1*</td>
<td>May/June</td>
<td>Sept/Oct</td>
<td>Dec 1</td>
</tr>
</tbody>
</table>

*Amended applications (new or renewal) are to be submitted on these dates.

Other components of ADAMHA and the National Institutes of Health (NIH) share an interest in several of the research areas described above. Projects may be submitted under this announcement that address issues in common with Institutes from either of these agencies. Joint funding of such projects is possible; however, preapplication consultation is strongly encouraged. Applications are considered for acceptance and assigned according to standing referral guidelines. Referencing this announcement does not guarantee assignment to the National Institute on Drug Abuse (NIDA).

Consequences of Late Submission

Applications received after the above receipt date are subject to assignment to the next review cycle or may be returned to the applicant.

Review and Review Criteria

The Division of Research Grants, NIH, serves as a central point for receipt of applications for most discretionary PHS grant programs. Applications received under this announcement will be assigned to an initial review group (IRG) in accordance with established PHS Referral Guidelines. The IRGs, consisting primarily of non-Federal scientific and technical experts, will review the applications for scientific and technical merit. Notification of the review recommendations will be sent to the applicant after the initial review.

Applications will receive a second-level review by an appropriate National Advisory Council. Only applications recommended for approval by the Council may be considered for funding.

Applications submitted in response to this Announcement are not subject to the intergovernment review requirements of Executive Order 12372, as implemented through Department of Health and Human Services regulations at 45 CFR Part 100 and are not subject to Health Systems Agency review.

Criteria for scientific/technical merit review of regular research grant applications will include the following: significance and originality from a scientific and technical standpoint of the goals of the proposed research; adequacy of the methodology proposed to carry out the research; qualifications of the Principal Investigator and other key research personnel; availability of adequate facilities, other resources, and collaborative arrangements necessary for the research; appropriateness of budget estimates for the proposed research activities, and adequacy of provisions for the protection of human subjects and welfare of animal subjects as applicable. Criteria for other support mechanisms are contained in separate program announcements available from NIDA staff.
Inquiries

Contact for Detailed Program Information:

Dr. Rao Rapaka
Research Technology Branch
Division of Preclinical Research
NIDA, Room 10A-13
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-5280

Contact for Review Procedures/Policies:

Dr. Rita Liu
Executive Secretary
Office of Extramural Program Review
NIDA, Room 10-42
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-1644 or 443-2620

Contact for a copy of the complete program announcement and for application kits, if not available from your business office:

Grants Management Branch
NIDA, Room 10-25
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-6710

FOOTNOTE: This program is described in the catalog of Federal Domestic Assistance No. 15.279. Grants will be awarded under the authority of Section 301 of the Public Health Service Act, as amended (42 USC 241) and administered in accordance with the PHS Grants Policy Statement and Federal regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.